A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer

  • Authors:
    • Kinya Furukawa
    • Junzo Ishida
    • Masaharu Inagaki
    • Kazuhiko Takabe
    • Shigemi Ishikawa
    • Mitsuaki Sakai
    • Hideo Ichimura
    • Koichi Kamiyama
    • Takayuki Kaburagi
    • Kenji Hayashihara
    • Koji Kishi
    • Makoto Saito
    • Hiroaki Satoh
  • View Affiliations

  • Published online on: October 7, 2011     https://doi.org/10.3892/etm.2011.360
  • Pages: 53-59
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There is no standard treatment and there are no clearly defined guidelines for the treatment of postoperative recurrent non-small-cell lung cancer (NSCLC). We performed a retrospective population-based study to assess the benefits of treatment with gefitinib in patients with a postoperative recurrence of NSCLC in general clinical practice. This retrospective population-based study was conducted on patients with postoperative recurrent NSCLC who had been treated with gefitinib at 14 institutions in Ibaraki Prefecture between July 2002 and September 2007. The objective response rate to gefitinib therapy was 37.6% for local and distant recurrence. The median survival time following the start of gefitinib therapy was 12 months, and the one-year and two-year survival rates were 48.9 and 28.9%, respectively. The median survival time of the females was 19 months, and the median survival time of the males was 9 months (p=0.002). Univariate analysis showed that female gender, adenocarcinoma, a performance status (PS) of 0-1 and absence of smoking history were favorable prognostic factors. Only female gender and a PS of 0-1 were independent statistically significant prognostic factors in the multivariate analysis. The rate of greater than grade 1 interstitial lung damage as an adverse event was 3.5%. Gefitinib is a feasible treatment for postoperative recurrent NSCLC in general clinical practice, and a good response and prolonged survival were obtained, similar to the findings reported in published clinical studies that were conducted on highly selected patients.
View Figures
View References

Related Articles

Journal Cover

January 2012
Volume 3 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Furukawa K, Ishida J, Inagaki M, Takabe K, Ishikawa S, Sakai M, Ichimura H, Kamiyama K, Kaburagi T, Hayashihara K, Hayashihara K, et al: A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer. Exp Ther Med 3: 53-59, 2012
APA
Furukawa, K., Ishida, J., Inagaki, M., Takabe, K., Ishikawa, S., Sakai, M. ... Satoh, H. (2012). A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer. Experimental and Therapeutic Medicine, 3, 53-59. https://doi.org/10.3892/etm.2011.360
MLA
Furukawa, K., Ishida, J., Inagaki, M., Takabe, K., Ishikawa, S., Sakai, M., Ichimura, H., Kamiyama, K., Kaburagi, T., Hayashihara, K., Kishi, K., Saito, M., Satoh, H."A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer". Experimental and Therapeutic Medicine 3.1 (2012): 53-59.
Chicago
Furukawa, K., Ishida, J., Inagaki, M., Takabe, K., Ishikawa, S., Sakai, M., Ichimura, H., Kamiyama, K., Kaburagi, T., Hayashihara, K., Kishi, K., Saito, M., Satoh, H."A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer". Experimental and Therapeutic Medicine 3, no. 1 (2012): 53-59. https://doi.org/10.3892/etm.2011.360